SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-013290
Filing Date
2023-04-26
Accepted
2023-04-26 17:22:34
Documents
14
Period of Report
2023-04-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20230426.htm   iXBRL 8-K 49271
2 EX-99.1 exhibit-99120230426.htm EX-99.1 47609
6 GRAPHIC logo.gif GRAPHIC 43773
  Complete submission text file 0001628280-23-013290.txt   309452

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20230426.xsd EX-101.SCH 1941
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20230426_lab.xml EX-101.LAB 24132
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20230426_pre.xml EX-101.PRE 12545
8 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20230426_htm.xml XML 11309
Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 23850889
SIC: 2836 Biological Products, (No Diagnostic Substances)